康沣生物-B(06922)完成发行559.5万股认购股份，净筹约2973万港元

智通财经

Jan 30

智通财经APP讯，康沣生物-B(06922)发布公告，认购协议A的所有条件已获达成，且认购协议A项下交易已于2026年1月30日完成。总计559.5万股认购股份已成功按每股认购股份认购价5.36港元向认购人A发行及配发。该559.5万股认购股份相当于紧接认购协议A完成前已发行H股数目约3.90%及现有已发行股份数目约2.34%;及紧随认购协议A完成后经配发及发行该559.5万股认购股份扩大后已发行H股数目约3.75%及现有已发行股份数目约2.29%。

经友好协商后，认购人B与本公司于2026年1月30日(交易时段后)订立终止协议，以终止认购协议B。根据终止协议，认购协议B的订约方须解除及免除其于认购协议B项下各自的义务，且概无任何一方须就因认购协议B产生或与其有关的任何事宜向另一方提出任何索偿。

由于认购协议B已终止，认购协议A所募集的所得款项总额将约为2999万港元，而所得款项净额将约为2973万港元。扣除所有相关开支后的认购价净额约为每股认购股份5.31港元。所有所得款项净额拟用于与血管介入、呼吸介入及肿瘤介入相关的微创介入产品的研发、生产及商业化，以及就该等产品商业化的潜在海外业务扩张。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2607016611"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2607016611\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2607016611?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-01-30 18:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607016611","market":"fut","top_or_hot":-1,"title":"康沣生物-B(06922)完成发行559.5万股认购股份，净筹约2973万港元","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/06922\">康沣生物-B</a>(06922)发布公告，认购协议A的所有条件已获达成，且认购协议A项下交易已于2026年1月30日完成。总计559.5万股认购股份已成功按每股认购股份认购价5.36港元向认购人A发行及配发。该559.5万股认购股份相当于紧接认购协议A完成前已发行H股数目约3.90%及现有已发行股份数目约2.34%;及紧随认购协议A完成后经配发及发行该559.5万股认购股份扩大后已发行H股数目约3.75%及现有已发行股份数目约2.29%。</p><p>经友好协商后，认购人B与本公司于2026年1月30日(交易时段后)订立终止协议，以终止认购协议B。根据终止协议，认购协议B的订约方须解除及免除其于认购协议B项下各自的义务，且概无任何一方须就因认购协议B产生或与其有关的任何事宜向另一方提出任何索偿。</p><p>由于认购协议B已终止，认购协议A所募集的所得款项总额将约为2999万港元，而所得款项净额将约为2973万港元。扣除所有相关开支后的认购价净额约为每股认购股份5.31港元。所有所得款项净额拟用于与血管介入、呼吸介入及肿瘤介入相关的微创介入产品的研发、生产及商业化，以及就该等产品商业化的潜在海外业务扩张。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康沣生物-B(06922)完成发行559.5万股认购股份，净筹约2973万港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康沣生物-B(06922)完成发行559.5万股认购股份，净筹约2973万港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-30 18:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1399884.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，康沣生物-B(06922)发布公告，认购协议A的所有条件已获达成，且认购协议A项下交易已于2026年1月30日完成。总计559.5万股认购股份已成功按每股认购股份认购价5.36港元向认购人A发行及配发。该559.5万股认购股份相当于紧接认购协议A完成前已发行H股数目约3.90%及现有已发行股份数目约2.34%;及紧随认购协议A完成后经配发及发行该559.5万股认购股份扩大后已发行...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1399884.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06922","symbol_name":"康沣生物-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1399884.html","article_id":"2607016611","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607016611","pubTimestamp":1769767435,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"总计559.5万股认购股份已成功按每股认购股份认购价5.36港元向认购人A发行及配发。该559.5万股认购股份相当于紧接认购协议A完成前已发行H股数目约3.90%及现有已发行股份数目约2.34%;及紧随认购协议A完成后经配发及发行该559.5万股认购股份扩大后已发行H股数目约3.75%及现有已发行股份数目约2.29%。由于认购协议B已终止，认购协议A所募集的所得款项总额将约为2999万港元，而所得款项净额将约为2973万港元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"06922":"康沣生物-B","BK1100":"医疗保健设备"},"translate_title":"Kangfeng Bio-B (06922) completed the issuance of 5.595 million subscription shares, raising a net of approximately HK $29.73 million","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06922":1.5},"content_text":"智通财经APP讯，康沣生物-B(06922)发布公告，认购协议A的所有条件已获达成，且认购协议A项下交易已于2026年1月30日完成。总计559.5万股认购股份已成功按每股认购股份认购价5.36港元向认购人A发行及配发。该559.5万股认购股份相当于紧接认购协议A完成前已发行H股数目约3.90%及现有已发行股份数目约2.34%;及紧随认购协议A完成后经配发及发行该559.5万股认购股份扩大后已发行H股数目约3.75%及现有已发行股份数目约2.29%。经友好协商后，认购人B与本公司于2026年1月30日(交易时段后)订立终止协议，以终止认购协议B。根据终止协议，认购协议B的订约方须解除及免除其于认购协议B项下各自的义务，且概无任何一方须就因认购协议B产生或与其有关的任何事宜向另一方提出任何索偿。由于认购协议B已终止，认购协议A所募集的所得款项总额将约为2999万港元，而所得款项净额将约为2973万港元。扣除所有相关开支后的认购价净额约为每股认购股份5.31港元。所有所得款项净额拟用于与血管介入、呼吸介入及肿瘤介入相关的微创介入产品的研发、生产及商业化，以及就该等产品商业化的潜在海外业务扩张。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}